Imatinib resistance in chronic myeloid leukaemia caused by Bcr-Abl kinase domain and non-Bcr-Abl mutations: a comparison and review. | Australian Medical Student Journal
Frontiers | Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation
Journal of Biomedical and Pharmaceutical Research
What is Gleevec? - Quora
Figure 2, Schematic model for the mechanism of action of Gleevec (imatinib) - Mechanistic Evidence in Evidence-Based Medicine: A Conceptual Framework - NCBI Bookshelf
Mechanism of action of Imatinib; Imatinib binds to the ATP binding site... | Download Scientific Diagram
Nilotinib Pathway, Pharmacokinetics/Pharmacodynamics
Mode of action of imatinib on BCR-ABL. ADP, adenosine diphosphate; ATP,... | Download Scientific Diagram
Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics | PLOS Computational Biology
Imatinib - Wikipedia
Defining molecular mechanisms of imatinib treatment in GIST - The Life Raft Group
Mode of action of imatinib. The phosphorylation of a substrate is shown... | Download Scientific Diagram
FDA licences imatinib mesylate for CML - The Lancet Oncology
Defining molecular mechanisms of imatinib treatment in GIST - The Life Raft Group
Immunological off-target effects of imatinib | Nature Reviews Clinical Oncology
Is there a cloud in the silver lining for imatinib? | British Journal of Cancer
Modern Therapy of Chronic Myeloid Leukemia | IntechOpen
Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events | Arteriosclerosis, Thrombosis, and Vascular Biology
Imatinib mechanism of action
Imatinib (Gleevec) - Oncology Nurse Advisor
Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update - Cytotherapy
Treatment of CML Transplant or Imatinib? Mark B Juckett MD Section of Hematology/BMT University of Wisconsin. - ppt download
Imatinib Mesylate — A New Oral Targeted Therapy | NEJM
Frontiers | Potential Approaches Versus Approved or Developing Chronic Myeloid Leukemia Therapy
Figure 3 from Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era? | Semantic Scholar
